Local 12: Chemotherapy in recurrent ovarian cancer patients
UC researcher publishes New England Journal of Medicine study looking at outcomes
The five-year survival rate for ovarian cancer is only 36%, one of the worst cancer survival rates out there.
Finding the right treatments, however, is critical to changing that survival rate, according to Dr. Thomas Herzog, a professor at UC and gynecologic oncologist with UC Health. His team just released a study in the New England Journal of Medicine comparing those who just had chemotherapy with a recurrent cancer and those who had chemotherapy in addition to surgery when the cancer came back.
Featured photo courtesy of Unsplash.
Related Stories
UC Board of Trustees approves $12 million for building design phase for new welcome gateway
March 13, 2026
The UC Board of Trustees approved $12 million at its Feb. 24 meeting for the design phase of a new Welcome Gateway Building for Uptown campus.
Breakthrough skin science discovery
March 12, 2026
A research collaboration between the University of Cincinnati and global cosmetics company Kose led to the creation of a novel anti aging spot fading serum.
UC co-op offers a glimpse into the future
March 12, 2026
UC engineering student Savannah Dickens wore many hats at companies during her co-op rotations. She will graduate this spring and a has a job lined up with Davey Resource Group in Akron, Ohio.